Nasdaq-100 boasts of some of the most exquisite and premium stocks, and Axon Enterprise is the latest addition to this Nasdaq Composite, which is under close scrutiny this week based on its recent volatility factors. However, whatever the case with Nasdaq 100, Axon remains a wonderful addition to the core, after it replaced biotechnology company Moderna, as part of Nasdaq-100’s annual rebalancing.
Axon Enterprise’s surreal growth makes it replace Moderna at Nasdaq Composite
Moderna, the company Axon replaced, had been performing quite well over the last couple of years, due to the demand of massive medications across the world due to the Covid-19 pandemic, as well as the need for vaccinations. However, its growth rate had come to a slight halt towards the end of 2024, and now Axon Enterprise will be taking its place, which is boasting of gain percentages of 110,600% since its IPO kicked off in the mid-2001s.
